These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 7561669)

  • 1. Measles, mumps, and rubella: monitoring in Switzerland through a sentinel network, 1986-94. Sentinella Arbeitsgemeinschaft.
    Matter HC; Cloetta J; Zimmermann H
    J Epidemiol Community Health; 1995 Aug; 49 Suppl 1(Suppl 1):4-8. PubMed ID: 7561669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mumps epidemiology in Switzerland: results from the Sentinella surveillance system 1986-1993. Sentinella Work Group].
    Zimmermann H; Matter HC; Kiener T
    Soz Praventivmed; 1995; 40(2):80-92. PubMed ID: 7747525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric sentinel surveillance of vaccine-preventable diseases in Italy.
    Ciofi Degli Atti ML; Salmaso S; Bella A; Arigliani R; Gangemi M; Chiamenti G; Brusoni G; Tozzi AE;
    Pediatr Infect Dis J; 2002 Aug; 21(8):763-8. PubMed ID: 12192166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L; Germann D; Bally F; Schopfer K
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel surveillance shows small decline in MMR coverage.
    Commun Dis Rep CDR Wkly; 1998 Sep; 8(36):317, 320. PubMed ID: 9782644
    [No Abstract]   [Full Text] [Related]  

  • 6. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
    N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence of rubella virus infections in Switzerland after the introduction of the MMR mass vaccination programme.
    Matter L; Bally F; Germann D; Schopfer K
    Eur J Epidemiol; 1995 Jun; 11(3):305-10. PubMed ID: 7493663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Field evaluation of the clinical effectiveness of vaccines against pertussis, measles, rubella and mumps. The Benevento and Compobasso Pediatricians Network for the Control of Vaccine-Preventable Diseases.
    Vaccine; 1998 May; 16(8):818-22. PubMed ID: 9627939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measles, mumps and rubella: control by vaccination.
    van Druten JA; de Boo T; Plantinga AD
    Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC; Burgess MA; O'Brien ED
    Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
    [No Abstract]   [Full Text] [Related]  

  • 12. Vaccination with a combined vaccine against measles, mumps and rubella aiming at elimination of the three diseases.
    Böttiger M; Christenson B; Strandell A; Romanus V
    Dev Biol Stand; 1986; 65():37-43. PubMed ID: 3556776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
    Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
    PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vaccination rate for triple measles-rubella-mumps vaccine in Empoli Val d'Elsa area health district U.S.L. 11, Tuscany Region].
    Salvadori P
    Ann Ig; 1998; 10(1):19-24. PubMed ID: 9616974
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland.
    Peltola H; Karanko V; Kurki T; Hukkanen V; Virtanen M; Penttinen K; Nissinen M; Heinonen OP
    Lancet; 1986 Jan; 1(8473):137-9. PubMed ID: 2867355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland.
    Johnson H; Hillary IB; McQuoid G; Gilmer BA
    Vaccine; 1995 Apr; 13(6):533-7. PubMed ID: 7483773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measles, mumps, and rubella vaccine coverage in 2 year old children in East Lancashire--better than it looks.
    Clark A; Marshall R
    Commun Dis Public Health; 1999 Jan; 2(1):50-3. PubMed ID: 10462897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mumps epidemic in vaccinated children in West Switzerland].
    Ströhle A; Eggenberger K; Steiner CA; Matter L; Germann D
    Schweiz Med Wochenschr; 1997 Jun; 127(26):1124-33. PubMed ID: 9312835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.